• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    2/5/26 4:01:41 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    artl_8k.htm
    0001621221false00016212212026-01-302026-01-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 30, 2026

     

    ARTELO BIOSCIENCES, INC.

    (Exact name of Company as specified in its charter)

     

    Nevada

     

    001-38951

     

    33-1220924

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    505 Lomas Santa Fe, Suite 160

    Solana Beach, CA USA

     

     

    92075

    (Address of principal executive offices)

     

    (Zip Code)

     

     

    (858) 925-7049

     

     

    (Company’s telephone number, including area code)

     

     

    ____________________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    ARTL

     

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On January 30, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an Equity Purchase Agreement, dated as of January 30, 2026 (the “Purchase Agreement”), with Square Gate Capital Master Fund, LLC – Series 5, a series limited liability company organized in the state of Delaware (“Square Gate”), pursuant to which the Company has the right, but not the obligation, to direct Square Gate to purchase up to $25 million (the “Initial Commitment Amount”) in shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”), which at the Company’s sole discretion can be increased by an additional $25 million once the Initial Commitment Amount has been exhausted (the “Maximum Commitment Amount”), subject to the terms and conditions contained in the Purchase Agreement (the “Square Gate Purchase Shares”).

     

    In consideration for Square Gate’s execution and delivery of the Purchase Agreement, the Company will issue 292,398 shares of Common Stock to Square Gate (the “Commitment Shares”), having an aggregate value, as of January 30, 2026, of $500,000, as shares and/or as pre-funded warrants. The Commitment Shares will be deemed fully earned on the date of the Purchase Agreement. In addition, the Company will be responsible for up to $35,000 of Square Gate’s customary due diligence and legal fees in connection with the Purchase Agreement.

     

    Concurrently with the execution of the Purchase Agreement, the Company and Square Gate also entered into a Registration Rights Agreement, dated as of January 30, 2026 (the “Registration Rights Agreement”), pursuant to which the Company agreed to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement within 30 calendar days of the Purchase Agreement, and to have such registration statement declared effective by the SEC within 60 calendar days of the Purchase Agreement (the “Initial Registration Statement”), to register under the Securities Act of 1933, as amended (the “Securities Act”), the offer and resale by Square Gate of all the Square Gate Purchase Shares that may be issued and sold by the Company to Square Gate from time to time under the Purchase Agreement and the Commitment Shares (collectively, the “Registrable Securities”). The Company must also file one or more additional registration statements for the resale of the Registrable Securities if necessary.

     

    During the term of the Purchase Agreement, the Company may direct Square Gate to purchase a certain portion of the Initial Commitment Amount (“Regular Put Amount”) by delivering a notice (“Put Notice”) to Square Gate. The Company shall, in its sole discretion, select the Regular Put Amount requested by the Company in each Put Notice. However, each requested Regular Put Amount may not exceed the lesser of (i) 100% of the average of the Average Daily Trading Volume (as defined in the Purchase Agreement) of the Common Stock over the five trading days preceding the trading day that a Put Notice is deemed delivered (the “Put Date”), (ii) thirty percent (30%) of the daily trading volume over the applicable Put Date, or (iii) $500,000, subject to waiver by Square Gate in its sole discretion. The purchase price to be paid by Square Gate for the Regular Put Amount will be 95% of the lowest daily VWAP (as defined in the Purchase Agreement) of the Common Stock during the three trading days immediately following the applicable Put Date (the “Regular Valuation Period”).

     

    During a Regular Valuation Period, the Company may submit one or more Put Notices to Square Gate, subject to Square Gate’s written acceptance, which shall state a number of additional shares of Common Stock (“Intraday Put Shares”) that the Company desires to sell to Square Gate on that same trading day. The purchase price to be paid by Square Gate for the Intraday Put Shares will be 95% of the lowest traded price during the Intraday Valuation Period (as defined in the Purchase Agreement). The maximum amount of Intraday Put Shares shall be 4.99% of the number of shares of Common Stock outstanding on the date of delivery of applicable Put Notice, which may be waived by Square Gate in its sole discretion.

     

    Each Put Notice is subject to the following limitations: (1) the Company may not conduct a sale under the Purchase Agreement to the extent that the effect would be the purchase and sale of an aggregate number of shares of Common Stock that would exceed 19.99% of the outstanding shares of Common Stock as of the date of the Purchase Agreement (the “Exchange Cap”), until either the Company obtains the requisite stockholder approval for issuances in excess of the Exchange Cap or the average price of all applicable sales equals or exceeds $1.71 per share, and (2) no Put Notice may cause the aggregate number of shares of Common Stock beneficially owned (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, by Square Gate and its affiliates as a result of previous issuances and sales of shares of Common Stock to Square Gate under the Purchase Agreement to exceed 4.99% of the then issued and outstanding shares of Common Stock.

     

    The Company will be prohibited from conducting any Variable Rate Transaction (as defined in the Purchase Agreement) without the prior written consent of Square Gate from any Put Date until the end of any Standstill Period (as defined in the Purchase Agreement); provided, however, that the Company may effect sales pursuant to a customary “at-the-market” facility with a FINRA-registered broker-dealer as sales agent.

     

     
    2

     

     

    The term of the Purchase Agreement began on the date of execution and ends on the earlier of (i) the date on which Square Gate shall have purchased shares equal to the Maximum Commitment Amount, (ii) January 30, 2029, (iii) provided that the Initial Registration Statement shall have been previously declared effective by the SEC, the written notice of termination by the Company to Square Gate (which shall not occur at any time that there is an outstanding Put Notice), or (iv) the written notice of termination by Square Gate to the Company if the Company receives a final delisting notice from the principal market or if the Common Stock fails to be listed on an eligible market.

     

    The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

     

    The Purchase Agreement and the Registration Rights Agreement are filed as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K, respectively, and the description above of the material terms of the Purchase Agreement and the Registration Rights Agreement is qualified in its entirety by reference to such exhibits.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated hereby reference.

     

    The securities that may be issued by the Company to Square Gate under the Purchase Agreement are being offered and sold by the Company to Square Gate in a transaction that is exempt from the registration requirements of the Securities Act, in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder. In the Purchase Agreement, Square Gate represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). Accordingly, the offer and sale by the Company of the securities that may be issued and sold to Square Gate under the Purchase Agreement have not been and will not be registered under the Securities Act or any applicable state securities or “Blue Sky” laws and, therefore, such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities or “Blue Sky” laws.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of any securities of the Company in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

     

    Description

    4.1

     

    Form of Pre-Funded Warrant

    10.1

     

    Equity Purchase Agreement, dated as of January 30, 2026, by and between Artelo Biosciences, Inc., and Square Gate Capital Master Fund, LLC – Series 5

    10.2

     

    Registration Rights Agreement, dated as of January 30, 2026, by and between Artelo Biosciences, Inc., and Square Gate Capital Master Fund, LLC – Series 5

    104

     

    Cover Page Interactive Data File (embedded within the XBRL document)

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 5, 2026

    ARTELO BIOSCIENCES, INC.

     

     

     

     

     

    /s/ Gregory D. Gorgas

     

     

    Name: 

    Gregory D. Gorgas

     

     

    Title:

    Chief Executive Officer and President

     

     

     
    4

     

    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Matsui Connie

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    2/2/26 4:57:43 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Blayney Douglas

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    2/2/26 4:53:50 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Emanuele Robert Martin

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    2/2/26 4:50:53 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

    SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today commented on the White House's recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol (CBD) products. Artelo views the Administration's action as a significant milestone in the recognition of CBD's therapeutic potential and an important step toward improving access to cannabinoid-based treatments f

    12/23/25 9:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models

    SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, partially funded by the Company, demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like eff

    12/3/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

    SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. "We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "We were very pleased with

    11/12/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artelo Biosciences upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

    7/8/25 8:21:40 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

    HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

    11/1/21 6:29:39 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

    LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

    2/12/21 7:33:23 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    SEC Filings

    View All

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    2/5/26 4:01:41 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Other Events

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    2/5/26 8:00:28 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    1/30/26 4:10:27 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    View All

    Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

    SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f

    10/27/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

    SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

    5/4/21 8:00:00 AM ET
    $KTRA
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

    LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

    3/9/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/9/22 11:08:31 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/4/22 3:19:12 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care